Results for tag: "Direct Acting Antiviral Drug"

Direct-acting antiviral drugs (DAAs) represent a class of pharmaceuticals specifically targeting viruses at the molecular level to prevent their proliferation. Within the broader category of infectious diseases drugs, DAAs are used mainly for the treatment of viral infections such as hepatitis C and can have a transformative effect by providing high cure rates and shortened treatment durations compared to older interferon-based therapies. These drugs act directly on viral enzymes and proteins critical to the viral life cycle, disrupting processes such as viral RNA replication and protein production. Their development has been a major advance in the therapeutic management of chronic viral infections, leading to substantial improvements in patient outcomes. The DAA market is characterized by innovation and rapid development of new therapies that offer improved efficacy and safety profiles. Key players in the direct-acting antiviral drug market include Gilead Sciences, Merck & Co., AbbVie Inc., and Bristol-Myers Squibb. Gilead Sciences, for example, is known for its portfolio of DAAs for the treatment of hepatitis C, which has redefined the standard of care in this therapeutic area. These companies are continuously engaged in the research and development of new DAAs that promise to enhance patient care and expand therapeutic options for various viral infections. Show Less Read more